PDE5 inhibitors: in vitro and in vivo pharmacological profile.

Article Details

Citation

Copy to clipboard

Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C

PDE5 inhibitors: in vitro and in vivo pharmacological profile.

Curr Pharm Des. 2009;15(30):3464-75.

PubMed ID

19860692 [ View in PubMed

]

Abstract

PDE5 inhibitors have been clearly established as first-line therapy for the treatment of erectile dysfunction (ED). Three PDE5 inhibitors--sildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis)--are currently approved by the FDA and the EMEA for use in ED, whereas sildenafil is also marketed under a different proprietary name (Revatio) for the treatment of pulmonary arterial hypertension (PAH). A forth PDE5 inhibitor, udenafil (Zydena), is currently marketed. In the present review the molecular basis and the mechanism of action of PDE5 inhibitors is discussed. In addition experimental and clinical data concerning their effects on different tissues, organs and systems is systematically reviewed and their possible beneficial action in numerous disorders is presented.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Udenafil	cGMP-specific 3',5'-cyclic phosphodiesterase	Protein	Humans	Yes	Inhibitor	Details